Literature DB >> 7162692

Parkinson's disease: a disorder due to nigral glutathione deficiency?

T L Perry, D V Godin, S Hansen.   

Abstract

Amino acid analysis of autopsied human brain showed reduced glutathione (GSH) content significantly lower in the substantia nigra than in other brain regions. GSH was virtually absent in the nigra of patients with Parkinson's disease. Oxidative degradation of L-DOPA and dopamine in vivo may generate reactive oxygen species (hydrogen peroxide, superoxide, hydroxyl radical, or singlet oxygen) which can damage membranes and other cellular components. Since GSH is an important natural antioxidant, a deficiency of GSH in the substantia nigra could make this region vulnerable to oxidative injury. If confirmed, the hypothesis that loss of nigrostriatal dopaminergic neurons results from a regional GSH deficiency could have important therapeutic implications for the management and prevention of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7162692     DOI: 10.1016/0304-3940(82)90390-1

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  136 in total

Review 1.  The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.

Authors:  K A Jellinger
Journal:  Drugs Aging       Date:  1999-02       Impact factor: 3.923

Review 2.  NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance.

Authors:  V Calabrese; T E Bates; A M Stella
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

3.  Liposomal-glutathione provides maintenance of intracellular glutathione and neuroprotection in mesencephalic neuronal cells.

Authors:  Gail D Zeevalk; Laura P Bernard; F T Guilford
Journal:  Neurochem Res       Date:  2010-06-10       Impact factor: 3.996

Review 4.  Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease.

Authors:  Julie K Andersen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

5.  NADPH-diaphorase-positive cell populations in the human amygdala and temporal cortex: neuroanatomy, peptidergic characteristics and aspects of aging and Alzheimer's disease.

Authors:  J W Unger; W Lange
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088

Review 6.  Parkinson's disease.

Authors:  C D Marsden
Journal:  Postgrad Med J       Date:  1992-07       Impact factor: 2.401

7.  Experimental strategy to identify genes susceptible to oxidative stress in nigral dopaminergic neurons.

Authors:  Myung S Yoo; Hibiki Kawamata; Dae J Kim; Hong S Chun; Jin H Son
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

Review 8.  Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.

Authors:  M Flint Beal
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

9.  Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway.

Authors:  Hoon Ryu; Junghee Lee; Beatrix A Olofsson; Aziza Mwidau; Alpaslan Dedeoglu; Maria Escudero; Erik Flemington; Jane Azizkhan-Clifford; Robert J Ferrante; Rajiv R Ratan; Alpaslan Deodoglu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

10.  A disruption in iron-sulfur center biogenesis via inhibition of mitochondrial dithiol glutaredoxin 2 may contribute to mitochondrial and cellular iron dysregulation in mammalian glutathione-depleted dopaminergic cells: implications for Parkinson's disease.

Authors:  Donna W Lee; Deepinder Kaur; Shankar J Chinta; Subramanian Rajagopalan; Julie K Andersen
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.